Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

NCT04790513 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia
Cardiovascular Diseases

Interventions

BIOLOGICAL: lerodalcibep
BIOLOGICAL: evolocumab
BIOLOGICAL: alirocumab

Sponsor

LIB Therapeutics LLC